The role of Anti-PAD4, Anti-CarP, and Anti-RA33 antibodies combined with RF and ACPA in predicting abatacept response in rheumatoid arthritis
Abstract Objectives To explore the role of newly emerging autoantibodies (AAbs) - peptidyl-arginine deiminase 4 (aPAD4), carbamylated proteins (aCarP), and anti-RA33 (aRA33) - alongside the traditionally assessed rheumatoid factor (RF) and anti-citrullinated protein antibodies (ACPA), in predicting...
Saved in:
| Main Authors: | Alberto Floris, Maria Maddalena Angioni, Mattia Fadda, Micaela Rita Naitza, Mattia Congia, Elisabetta Chessa, Matteo Piga, Alberto Cauli |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
BMC
2025-01-01
|
| Series: | Arthritis Research & Therapy |
| Subjects: | |
| Online Access: | https://doi.org/10.1186/s13075-024-03470-y |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
EXPERIENCE WITH ABATACEPT IN TREATMENT OF JUVENILE IDIOPATHIC ARTHRITIS
by: Margarita Fedorovna Dubko, et al.
Published: (2012-10-01) -
Experience with abatacept used in the treatment of patients with rheumatoid arthritis
by: V I Mazurov, et al.
Published: (2011-12-01) -
Anti-cyclic citrullinated peptide antibodies – a role in rheumatoid arthritis and the possibility of seroconversion: A focus on abatacept
by: N. V. Chichasova
Published: (2017-03-01) -
Abatacept and cardiovascular risk in rheumatoid arthritis: update
by: T. V. Popkova
Published: (2018-01-01) -
EXPERIENCE OF ABATACEPT TREATMENT IN A PATIENT WITH SEROPOSITIVE POLYARTHRITIS FROM RISK GROUP OF TUBERCULOSIS INFECTION
by: L. A. Balykova, et al.
Published: (2013-12-01)